Dr. Reddy’s Laboratories (NYSE:RDY) Posts Earnings Results, Beats Estimates By $0.01 EPS

Posted by Denise Davis on Jan 25th, 2025

Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) announced its earnings results on Thursday. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.01, Zacks reports. Dr. Reddy’s Laboratories had a return on equity of 18.53% and a net margin of 17.81%.

Dr. Reddy’s Laboratories Stock Performance

Shares of NYSE RDY opened at $14.02 on Friday. The firm has a market capitalization of $11.70 billion, a price-to-earnings ratio of 22.39 and a beta of 0.51. Dr. Reddy’s Laboratories has a one year low of $13.61 and a one year high of $16.89. The business has a fifty day simple moving average of $14.86 and a 200 day simple moving average of $15.52. The company has a current ratio of 1.92, a quick ratio of 1.36 and a debt-to-equity ratio of 0.02.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on RDY shares. StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th. Barclays decreased their price target on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th. Finally, Nomura lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th.

Read Our Latest Report on RDY

Dr. Reddy’s Laboratories Company Profile

(Get Free Report)

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.